The DZNE does not only conduct locally designed studies at the individual sites. Due to its structure, it is possible that subjects in multicenter studies can be examined at all participating DZNE sites.
Researchers at the DZNE and at the cooperating institutions are looking for volunteer study participants:
- At nine German sites, the DZNE is conducting studies in at-risk individuals and those affected by a neurodegenerative disease (e.g., Alzheimer's, dementia, or Parkinson's disease).
- In addition, we are also looking for healthy study subjects and relatives of persons with neurodegenerative diseases.
- Depending on the study, an expense allowance will be paid.
If you would like to support our research by participating, here you will find an overview of all clinical studies for which the DZNE is currently looking for participants.
You can refine your search using the filters for the target group, a specific diagnosis and a certain DZNE site.
7T-TGA (high-resolution MRI imaging in TGA patients: a retrospective and prospective study)
High-resolution MRI imaging as evidence of a structural cause in transient global amnesia (TGA), in which there is disruption of anterograde and also retrograde memory such that newly learned or experienced material is not retained.
ABCD
The aim of this study is to investigate the influence of rituximab (Rixathon®) on the progression of disease in patients with amyotrophic lateral sclerosis (ALS) compared to a placebo. The study is funded by the German Federal Ministry of Education and Research (BMBF).
ALS-FTD Cognition (Attention and memory functions in amyotrophic lateral sclerosis and frontotemporal dementia)
Amyotrophic lateral sclerosis and frontotemporal dementia are two diseases caused by a progressive loss of neurons in the brain. Since these two diseases are poorly understood, we are interested in higher mental performance, especially attentional functions, in these two diseases.
AMBLIND (Autobiographical memory in blind people)
We often remember past experiences with the help of our visual imagination. But how do people who are blind from birth or later become blind imagine past experiences? Which brain regions are addressed and how does this differ from sighted people?
Aphantasia (Neural correlates of aphantasia: assessments using functional magnetic resonance imaging)
>>> Study already completed! <<< To investigate the causes and consequences of aphantasia, aphantasists as well as unaffected control subjects are sought.
ApoE Navi (Influences of the APOE-ε4 genotype and other Alzheimer´s disease (AD) related genes on spatial navigation ability and its neural basis)
The relationship between spatial orientation ability and the context dependence of spatial representations in entorhinal cortex and hippocampus in APOE-ε4 allele carriers is investigated.
ApoE Sleep (Influence of the Apolipoprotein-E Genotype on Brain Activity during Sleep and Wakefulness)
>>> Study already completed! <<< EEG/fMRI measurements during quiet wakefulness and sleep to investigate neurovascular coupling during different sleep stages depending on ApoE genotype.
ARCA (Autosomal-Recessive Cerebellar Ataxias)
In this DZNE network research project (Autosomal Recessive Cerebellar Ataxia Registry, ARCA registry), modern methods are being used to search for new ataxia genes and biomarkers in autosomal recessive ataxias and early onset ataxias with onset before the age of 40.
BonSEP (Long-Term Cognitive and Cerebral Changes in Sepsis Survivors and their Predictors)
>>> Study already completed! <<< Sepsis (blood poisoning) is an inflammatory reaction that affects the entire body and the recovery process is very protracted. Impairments in the normal everyday life of convalescents due to limitations in resilience, sleep disturbances, memory and concentration problems may be caused by neurodegenerative processes.
CELIA (A trial for the treatment of mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia with BIIB80))
The CELIA study investigates a therapeutic option for Alzheimer's disease by focusing on a protein called tau. It is examining whether different doses of the study drug BIIB080 have potential side effects and can influence the progression of Alzheimer's disease.
COG-HF (Mechanisms of cognitive impairment in chronic heart insufficiency)
Chronic heart failure (chronically reduced pumping capacity) can lead to impairments in memory or other mental functions. The causes of this are still mainly unclear and will be investigated in this study.
Corona and cognition (The effects of restrictions caused by the coronavirus SARS-CoV-2 on cognitive health and dementia prevention)
This study examines the effects of social, emotional, and occupational changes due to SARS-Co-V2 coronavirus limitations on cognition and prevention of mental decline.
Costs of specialized dementia diagnostics using the example of the Memory Klinik of the University of Rostock
By analysing the total costs of specialised dementia diagnostics, it should be made possible to measure the resulting costs for the memory clinic, given a known patient volume, and thus provide a basis for estimating the diagnostic costs of dementia for society as a whole.
DANCER (Establishment of a Recruitment Pool of Potential Study Participants, of Realtives and a Control Group for DZNE Studies)
One focus of these studies is the identification of early, specific changes, for example in the blood, so that the diagnosis of a neurodegenerative disease such as dementia or Parkinson's can be made at a very early stage. This enables a better understanding of the diseases and supports the development of new forms of therapy.
DANCER-FTD (Recruitment of Realtives and a Control Group for the DESCRIBE-FTD Study)
In order for us to assess study outcomes of patients with neurological frontotemporal dementia (FTD), comparative studies with relatives of patients with FTD as well as interested individuals without a diagnosis of neurodegenerative disease are needed.
DANCER-PSP (Recruitment of Realtives and a Control Group for the DESCRIBE-PSP Study)
Comparative studies with relatives of patients with PSP and interested individuals without a diagnosis of neurodegenerative disease are needed to assess study outcomes of patients with progressive supranuclear palsy (PSP).
DCAAS (DZNE Cerebral Amyloid Angiopathy Study)
Cerebral amyloid angiopathy (CAA) is a disease of the vessels in the brain in which proteins, known as amyloid, are deposited in the walls of the vessels. There are initial indications of possible mechanisms and biomarkers that influence the course of the disease, but there are still many unanswered questions.
DELCODE (DZNE - Longitudinal Cognitive Impairment and Dementia study)
Early detection of Alzheimer's disease, if possible, before the onset of symptoms or at the first mild symptoms as a prerequisite for the development of therapies.
DEMDAS (DZNE - Mechanisms of Dementia After Stroke Study)
The risk of developing post-stroke dementia (PSD) after a stroke is high, but the causes are poorly understood.
DESCRIBE (DZNE - Clinical Register Study of neurodegenerative Disorders)
The aim of the DESCRIBE study is to use the examination results obtained in the course of normal patient care together with findings from diagnostics on biomaterials, including genetic analysis, for scientific purposes.
DESCRIBE-FTD (DZNE - Clinical Registry Study on Frontotemporal Dementia (FTD))
The aim of the DESCRIBE-FTD study is to describe in detail the course of FTD in its various clinical manifestations. The aim is to gain a better understanding of the underlying pathology and to identify parameters that enable diagnosis and prediction of the course of the disease.
DESCRIBE-PSP (DZNE - Clinical Registry Study on Progressive Supranuclear Paresis (PSP))
The aim of the DESCRIBE-PSP study is to document the early and atypical course of PSP in order to enable improved diagnostic criteria and therapy studies in the early course of the disease.
DIAN (Longitudinal Study on Dominantly Inherited Alzheimer's Disease)
Hereditary Alzheimer's disease, caused by gene mutations, is extremely rare - but those who carry it inevitably develop dementia, usually even before the age of 60. The DIAN network wants to gain insights from this for the very common sporadic Alzheimer's dementia and future therapies.
DZNE Clinical Ataxia Network
Overview of studies belonging to the DZNE Clinical Ataxia Network.
Education for relatives "Living with dementia"
Training series for relatives: Positive effects in care by providing background knowledge and showing possibilities in the daily handling of people with dementia as well as suitable relief and care strategies so that people with dementia can be cared for longer in the home.
ENABLE (Patient- and care-related benefits of amyloid PET imaging)
The aim of the ENABLE trial is to test whether amyloid PET screening has the potential to improve the care of dementia patients in the German health care system and thus contribute to the preservation or slowed loss of everyday functions.
EPI589-15-002(Phase 2A safety and biomarker study of the drug substance EPI-589 in patients with mitochondrial subtype of Parkinson's disease)
>>> Study already completed! <<< The primary objective of the study is to assess the safety of EPI-589 when applied to patients with idiopathic and genetic Parkinson's disease (e. g. hematology, electrocardiogram).
EPND Glossary Feedback Survey
The European Platform for Neurodegenerative Diseases (EPND) Glossary was established to provide the basis for a consistent, high-quality use of terminology for neurodegenerative diseases.
EQ-5D-ATAX (Psychometric properties of the EQ-5D in rare ataxia diseases)
Study on the suitability of the EQ-5D questionnaire as a suitable instrument to assess health-related quality of life in patients with rare ataxia disorders.
ESMI (European Spinocerebellar Ataxia Type 3/Machado-Joseph Disease Initiative)
The aim of this study is to assemble a trial-ready cohort of sufficient size consisting of patients with spinocerebellar ataxia type 3 (SCA 3) and first-degree relatives, so-called at-risk individuals, for future drug trials.
Eye and neurodegeneration
>>> Study already completed! <<< Eye and neurodegeneration: Changes in nerve fibers and vessels in the eye in neurodegenerative diseases.
Functional Importance of the Noradrenaline System in connection with Memory Impairments and Alzheimer's Disease
GENERATION HD1 (Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease)
>>> Study already completed <<< The GENERATION HD1 study will evaluate the efficacy and safety of treatment with RG6042 administered once every two months (every eight weeks) or once every four months (every 16 weeks) over a 25-month period. This modified global study will enroll up to 660 patients with manifest Huntington's disease (HD) at 80-90 centers worldwide.
GENERATION HD2 (Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen (R) in Individuals with Prodomal and Early Manifets Huntigton's Disease)
This study will enroll up to 360 people with early manifest Huntington's disease or carriers of the abnormal huntingtin gene with very early, subtle symptoms of HD. The GENERATION HD2 study will evaluate the safety, biomarkers and efficacy of the investigational drug tominersen, which will be administered over a period of 16 months.
GenHighfield (Study of the Influence of Apolipoprotein-E Polymorphisms on the Structure and Function of Hippocampus Formation, using EEG and Ultra-High-Field 7T MRI)
>>> Study already completed! <<< In this study, the influence of the apolipoprotein E gene on the structure (MRI) and activity (fMRI) as well as on the oscillatory EEG activity of specific hippocampal subregions was investigated.
HSP-Net (Networking Project on Hereditary Spastic Paraplegia)
Spastic spinal paralysis (HSP) is a rare, often hereditary, slowly progressive disease characterized by a spastic gait disorder. The HSP project involves the establishment and conduct of a multicenter study of the natural longitudinal course of hereditary spastic spinal paralysis.
IONIS-MAPTRX-CS1 (A placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered ISIS 814907 in patients with mild Alzheimer’s disease)
>>> Study already completed! <<< With this study, doctors want to investigate the safety and efficacy of the investigational drug and compare it to a placebo that looks like the investigational drug but contains no active ingredients.
Locus Coeruleus-to-Pons Intensity Ratio as Clinical Biomarker for AD
This study investigates whether patients with different stages of dementia can be accurately diagnosed using LC-to-pons intensity ratio on neuromelanin-sensitive MRI images.
M-Star (placebo-controlled, parallel-group study to evaluate the efficacy and safety of BHV-3241 in subjects with multiple system atrophy)
>>> Study already completed! <<< Our team of physicians is studying a study drug designed to suppress an enzyme called myeloperoxidase (MPO), which is believed to cause inflammation and damage to neurons in the brains of patients with multisystem atrophy.
MiGAP (Markers in GBA-associated Parkinson's Disease – Early Detection, Progression, Mechanisms, Protection)
The aim of the MiGAP study is a geno-phenotypic characterization of GBA-associated Parkinson's disease with respect to motor and non-motor symptoms and the identification of specific biomarkers in blood, CSF and cell models.
New Biomarkers of Dementia - MRI, fNIRS, DC-Potential, Herzfrequenz
>>> Study already completed! <<< The study addresses the combination of physiological parameters that can potentially detect declining brain function in dementia at an early stage.
NIO752 (Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy)
Adult patients suffering from progressive supranuclear gaze palsy (PSP) are eligible for enrollment in this study. Gaze palsy is a form of atypical Parkinson's syndrome.
ORCHESTRA (Clinical research study to evaluate the use of an investigational medication called UCB0599 in men and women with early-stage Parkinson’s disease)
This study investigates the safety, tolerability, and pharmacokinetics of orally administered UCB0599 in study participants with early-stage Parkinson's disease.
PASADENA - A Placebo-controlled study to evaluate the efficacy of intravenous RO7046015 (PRX002) in patients with early Parkinson’s disease
PRAISE (Prediction of acute coronary syndrome in acute ischemic stroke)
Among patients with ischaemic stroke and concomitant troponin elevation, identify those in whom acute coronary syndrome underlies the troponin elevation.
PROFA (Patient-reported, health economic and psychosocial outcomes in Friedreich Ataxia)
Investigation of the impact of Friedreich's ataxia on patient-related, health economic, and psychosocial outcomes using self-reported data collection via a patient-centered e-health app.
PROSA (A Low-burden High-frequency PROgnostic Digital Speech Biomarker to Improve Future Confirmatory ALS and FTD Trials)
Development and validation of a novel speech biomarker for the ALS-FTD disease spectrum based on speech measurements that can be collected repeatedly and remotely by telephone to assess three key symptom groups: Cognition (language, executive functions and memory), motor function and respiratory function.
Prospect-AD (Population-based screening over speech for clinical trials in Alzheimer’s Disease)
Subjective memory impairment (SCD) or mild cognitive impairment (MCI) may be associated with an increased risk of dementia later in life. Early preventive measures can potentially reduce the risk of dementia. This requires early detection of early signs of cognitive impairment.
REMINDer (Online study to evaluate the feasibility and effectiveness of a multimodal online exercise program for elderly adults)
The DZNE Dresden is investigating the feasibility and effectiveness of a six-week multimodal online program with music, movement and mindfulness exercises for people aged 60 - 80 years.
SCA Registry (Registry for Spinocerebellar Ataxies (SCA))
The goals of the SCA Registry are to characterize the natural history of the disease, identify prognostic factors, and develop novel imaging and biochemical biomarkers. By including at-risk individuals, we place a special focus on studying the preclinical disease phase.
SPORTAX-NHS (Observational Study on Adult Onset Sporadic Ataxias)
The SPORTAX study aims to precisely characterize the two forms of the disease and to compare the courses of the disease. In addition, factors are to be identified that allow a more precise assignment of the disease at an early stage and that can influence the development of the disease.
StimMem (Effects of transcranial electrical brain stimulation on memory)
>>> Study already completed! <<< To investigate whether transcranial alternating current stimulation (tACS) can be used to influence associative memory function in healthy adults. This project will provide the basis for assessing whether tACS can potentially be used to improve declining memory function in patients with memory impairment.
TAK-341-2001 (A Study of TAK-341 in Treatment of Multiple System Atrophy)
This study helps answer important medical questions about an investigational drug called TAK-341, such as: How effective is it in treating people who have MSA? What side effects may occur?
TrainParC (Cognitive training for the therapy of mild cognitive disorders (PD-MCI) of Parkinson's disease)
>>> Study already completed! <<< The aim of this randomized controlled trial is to evaluate to what extent a six-week cognitive training in small groups (5-8 participants), compared to a control training (stretching training), improves the cognitive performance of PD-MCI patients in the short term and to what extent the training prevents further cognitive performance decline.
TREND (Tübinger evaluation of Risk factors for Early detection of NeuroDegeneration)
Symptoms as risk factors – early detection is very important. The neurodegenerative process in the prodromal phase is associated with several symptoms that may indicate an increased risk for Parkinson’s or Alzheimer’s disease.
VO659-CT01 (A study on Vo659 in the treatment of Spinocerebellar Ataxia Type 1, 3 and Huntington's disease)
This clinical trial is open to patients with SCA1, SCA3 and Huntington's disease, a group of rare, congenital genetic disorders that affect specific areas of the brain. The disorders can cause disturbances in balance, coordination, walking, swallowing and speech, as well as mental and psychological problems.
Vorinostat_AD (A dose-finding study to address safety (and efficacy) of Vorinostat in Alzheimer‘s Disease)
The objective of this clinical trial is to determine a tolerable and tolerable dose of the drug vorinostat in elderly patients with mild Alzheimer's disease.